DEBIOPHARM
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the signing of an exclusive licensing agreement with Genome & Company (http://genomecom.co.kr/), a publicly-traded, South Korea-based, biotechnology company focusing on discovery and development of novel target antibody therapeutics, for the development of antibody drug conjugates (ADCs) with first-in-class potential. The agreement offers Debiopharm exclusive global rights to develop ADCs combining specific Genome and Company antibodies with Debiopharm’s innovative linker technology, Multilink™, to create highly innovative therapeutic agents to outsmart hard-to-treat cancers.
ADCs are cutting-edge oncology therapeutics that combine three components: a monoclonal antibody, a stable linker and one or more potent cytotoxic payload. These targeted compounds identify and dock onto specific antigens on cancer cell surfaces and promote targeted delivery of toxic payloads to antigen-expressing cancer cells. This modality improves therapeutic effectiveness while diminishing systemic toxicity and side effects typically associated with conventional cancer treatments. This distinctive capacity to selectively eliminate cancer cells while preserving healthy tissues has granted visibility to ADCs within the pharmaceutical development community. With the ever-growing interest in ADC development, linker design has increasingly become a critical determining factor, as few linkers provide satisfactory stability required for specific and effective drug release.1
“Building on our fruitful collaboration with Genome & Company, the potential of developing this novel antibody family with our proprietary MultilinkTM cleavable linker technology is an exciting opportunity. We recognized that Genome’s innovative antibodies were the right fit for our development focus due to the novelty of the target and its expression in tumor types with high unmet needs” expressed Frederic Levy, Chief Scientific Officer. “This extended collaboration with Genome & Company’s antibody against a novel target represents our commitment to form strategic partnerships for the development of first-in-class and best-in-class ADCs leveraging our proprietary Multilink™ technology, offering unique linker characteristics that grant a higher stability and DAR, thereby optimizing treatment specificity and effectiveness.”
Debiopharm is focused on further expanding their ADC platform, exploring proprietary novel bispecific ADCs and potential game changing technologies such as novel payloads, dual payloads, and degraders, leveraging their solid drug development experience to accelerate ADC products to patients.
“This agreement represents our first out-license deal in the field of novel target anti-cancer therapy of Genome & Company, and we were able to achieve meaningful results in early preclinical stage based on our excellent research and development capabilities,” commented Yoo Seok Hong, CEO of Genome & Company. “We expect to show results from our subsequent pipeline of novel target anti-cancer drugs in the near future, leveraging this license deal.”
About Multilink™
Multilink™ is a new cleavable linker platform suited for multidrug attachment and compatible with any conjugation technology to produce ADCs with high DAR (drug-to-antibody ratio). This unique and innovative technology allows the loading of multiple payloads on an antibody for an enhanced therapeutic effect. This highly effective and well-tolerated linker platform is available for use by other specialty biotech or pharmaceutical companies to generate proprietary, clinical-stage ADCs.
Debiopharm’s ADC Portfolio
Our ADC portfolio consists of carefully selected targets with 1st-in-class or best-in-class potential, including Debio 1562M, a CD37-targeted ADC for the treatment of acute myeloid leukemia (AML) Myelodysplastic syndromes (MDS) and Debio 0532, an HER3-targeted ADC for solid tumors. Key partnerships also comprise options to in-licence bispecific antibodies targeting HER2-HER3 and HER3-EGFR along with other further undisclosed targets. Our ADCs are designed with MultiLinkTM proprietary cleavable linker technology, allowing both high DAR and high stability. Debio 1562M, the CD37 ADC with a novel DM1 derivative payload, represents our most advanced program, expected to reach the clinic in 2025. We are continuing to invest in our ADC platform, exploring potential game changing technologies such as novel and dual payloads or degraders, leveraging our solid development experience to accelerate ADC products to patients.
About Genome & Company
Genome & Company is a South Korean-based biotechnology company specializing in discovery and development of novel cancer target antibodies as stand-alone therapy and antibody-drug conjugate (ADC) applications. The company leverages its GNOCLE™ drug discovery and development platform, a unique bed-to-bench approach based on real-world clinical data. For more information, please refer to our website http://www.genomecom.co.kr
About Debiopharm
Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and international patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.
Visit us www.debiopharm.com
Follow us on X @DebiopharmNews at http://twitter.com/DebiopharmNews
Follow us on LinkedIn
References:
- Zheng Su et al. Acta Pharmaceutica Sinica B 2021;11(12):3889e3907
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603093689/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ageneau Group Chooses Generix WMS to Boost Growth21.1.2026 09:00:00 CET | Press release
Generix, a global business software company offering an expansive portfolio of SaaS solutions for supply chain, finance, commerce, and B2B integration, announces that Ageneau Group, a French transportation, logistics, and training company, has chosen Generix WMS and TradeXpress to modernize operational processes at its Angers (Trélazé) site, which has a covered area of 9,000 m² and state-of-the-art technological equipment, including automated guided vehicles (AGVs). “We needed a powerful and scalable tool that was in line with our values of cohesion, respect, and innovation. Generix was able to meet 100% of our specifications and support us with transparency and expertise,” said Arnaud Ageneau, co-director of processes, purchasing, and IT at the Ageneau Group. To support its growth and meet the changing needs of its customers, the Ageneau Group was looking for a solution capable of digitizing its operations, optimizing its flows, and providing advanced logistics to its teams. The group
International Zinc Association Partners With Pharmanova to Save Children in Zambia21.1.2026 09:00:00 CET | Press release
Zinc Saves Kids, a global child‑health initiative of the International Zinc Association (IZA), has announced a new partnership with leading Zambian pharmaceutical manufacturer Pharmanova Zambia Limited to expand access to life‑saving zinc treatments for children across Zambia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121178091/en/ Life-saving zinc-supplementation and oral rehydration salts kits are proactively distributed to Zambian children through the works of the International Zinc Association, Pharmanova, and the Zambian Ministries of Health and Education. The collaboration was formally celebrated during a ceremony in Lusaka with the Zambian Ministry of Health, Pharmanova Zambia Limited, and IZA represented by Environment Health & Sustainability Director Dr. Eric Van Genderen. IZA and Pharmanova have united in an effort to scale up treatment for childhood diarrhea using zinc, an essential micronutrient that stre
LatticeFlow AI Acquires AI Sonar, the Leading AI Discovery Platform, to Enable End-to-End, Secure AI Governance21.1.2026 08:22:00 CET | Press release
The acquisition establishes LatticeFlow AI as the industry’s first evidence-based AI governance solution, securely connecting on-prem AI discovery and evaluation with centralized governance operations LatticeFlow AI, a Swiss deep-tech company leading evidence-based AI governance, today announced during the World Economic Forum (WEF) the acquisition of Dublin-based AI Sonar Ltd, a wholly owned subsidiary of CloudSphere Ltd. AI Sonar’s leading edge AI discovery platform allows enterprises and ISVs to detect shadow AI. AI Sonar’s solution will continue to be offered under its brand name by LatticeFlow AI. With this acquisition, LatticeFlow AI will introduce the industry’s first end-to-end, evidence-based AI governance solution securely connecting on-prem AI discovery and evaluations with centralized SaaS governance operations, and covering GenAI, agentic and traditional AI systems. As part of the acquisition, LatticeFlow AI assumes full ownership of AI Sonar’s platform, intellectual prope
Ramboll and Acutro Form Strategic Alliance to Drive Smarter, More Sustainable Intelligent Buildings21.1.2026 08:13:00 CET | Press release
Ramboll, a global leader in engineering, architecture, and consultancy, has entered into a strategic, collaborative partnership with Acutro, specialists in building performance improvement and predictive, data-led maintenance. The partnership brings together Ramboll’s global engineering expertise and Acutro’s digital building intelligence capabilities, creating synergies that support innovation, learning, and value creation for both organisations and their clients. The collaboration enables Ramboll to explore advanced building intelligence tools that can strengthen its digital design capability, while providing Acutro with the opportunity to apply and evolve its platform across complex, real-world projects. Together, the partners will help clients make more informed decisions about performance, lifecycle value, and operational risk. The multi-year relationship provides Ramboll with access to Acutro’s cloud-native platform, creating opportunities to integrate real-time performance analy
STREAMWIDE Marks Major APAC Milestone with UPCAD Public Safety Deployment in the Philippines21.1.2026 08:00:00 CET | Press release
STREAMWIDE has been selected by UPCAD (Unified Platform for Communication and Dispatch) of the Philippines to power its next generation critical communications platform for first responders integrated with national 911 call centers. Through this collaboration, UPCAD integrates STREAMWIDE’s field proven mission critical technology with the national 911 services, the new solution is designed to ensure uninterrupted, secure, and reliable communication during emergencies, enabling faster response times, improved situational awareness, and enhanced public safety outcomes. By integrating directly with 911 call centers, the platform enables real-time sharing of critical information such as caller location, incident details, and response status with first responders and command teams. Through our API, the platform integrates digital workflow capabilities, allowing information to flow seamlessly into the same system. This enables up-to-date reporting while automatically creating incident workfl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom